6XP logo

Xspray Pharma BST:6XP Stock Report

Last Price

€3.72

Market Cap

€121.1m

7D

0%

1Y

n/a

Updated

24 Nov, 2024

Data

Company Financials +

6XP Stock Overview

A pharmaceutical company, engages in the development of protein kinase inhibitors for targeted cancer treatments in Sweden. More details

6XP fundamental analysis
Snowflake Score
Valuation1/6
Future Growth5/6
Past Performance0/6
Financial Health6/6
Dividends0/6

Xspray Pharma AB (publ) Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Xspray Pharma
Historical stock prices
Current Share PriceSEK 3.72
52 Week HighSEK 7.63
52 Week LowSEK 3.66
Beta0.84
11 Month Change-30.86%
3 Month Changen/a
1 Year Changen/a
33 Year Changen/a
5 Year Changen/a
Change since IPO-36.77%

Recent News & Updates

Recent updates

Shareholder Returns

6XPDE BiotechsDE Market
7D0%-0.7%-0.02%
1Yn/a-17.2%8.2%

Return vs Industry: Insufficient data to determine how 6XP performed against the German Biotechs industry.

Return vs Market: Insufficient data to determine how 6XP performed against the German Market.

Price Volatility

Is 6XP's price volatile compared to industry and market?
6XP volatility
6XP Average Weekly Movementn/a
Biotechs Industry Average Movement6.5%
Market Average Movement4.8%
10% most volatile stocks in DE Market10.9%
10% least volatile stocks in DE Market2.3%

Stable Share Price: 6XP's share price has been volatile over the past 3 months compared to the German market.

Volatility Over Time: Insufficient data to determine 6XP's volatility change over the past year.

About the Company

FoundedEmployeesCEOWebsite
200324Per Anderssonwww.xspraypharma.com

Xspray Pharma AB (publ), a pharmaceutical company, engages in the development of protein kinase inhibitors for targeted cancer treatments in Sweden. The company’s product candidates include Dasynoc, a trailblazer, under approval phase for the treatment of chronic myeloid leukemia and acute lymphoblastic leukemia; XS003, an amorphous non-crystalline nilotinib, under pivotal studies for the treatment of chronic myeloid leukemia; XS008, based on axitinib, under development for treatment of kidney cancer; and XS00Y under development phase. It has partnership agreements with EVERSANA for the commercialization of Dasynoc, as well as with NerPharMa for commercial production of Dasynoc.

Xspray Pharma AB (publ) Fundamentals Summary

How do Xspray Pharma's earnings and revenue compare to its market cap?
6XP fundamental statistics
Market cap€121.11m
Earnings (TTM)-€22.44m
Revenue (TTM)n/a

0.0x

P/S Ratio

-5.4x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
6XP income statement (TTM)
RevenueSEK 0
Cost of RevenueSEK 0
Gross ProfitSEK 0
Other ExpensesSEK 258.05m
Earnings-SEK 258.05m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

Feb 12, 2025

Earnings per share (EPS)-7.64
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0%

How did 6XP perform over the long term?

See historical performance and comparison